Telesis Bio Inc

Telesis Bio, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Sanofi

The deal represents a 56% premium to Translate Bio's volume-weighted average price per share over the past 60 days.

Translate Bio soars 30% after Sanofi agrees to buy the mRNA company for $3.2 billion

Shares of Translate Bio Inc. soared 29.8% in premarket trading on Tuesday after Sanofi said it will spend $3.2 billion to buy the developer of messenger RNA (mRNA) technologies. The U.S.-listed shares of Sanofi were down 0.1% in premarket trade.

Sanofi to buy mRNA developer for $3.2 billion

Sanofi SA (NASDAQ: SNY) has announced it is buying Translate Bio (NASDAQ: TBIO) in a deal valued at about $3.2 billion. These are the details.

Why Sanofi (SNY) Is Buying Translate Bio (TBIO) For $3.2 Billion

A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion buyout for Translate Bio. Sanofi will pay $38 in cash for each of Translate Bio's shares, a 30% premium to Monday's closing price of $29.15.

Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights

Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.

Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA Tech

Sanofi to acquire U.S.-based Translate Bio in deal valued at $3.2 billion

French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio

-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi's recently announced  mRNA Center of Excellence --

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development

PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Exclusive-Sanofi offers to buy U.S. mRNA partner Translate Bio -sources

Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Translate Bio, Inc. (TBIO) Report Negative Q2 Earnings? What You Should Know

Translate Bio (NASDAQ:TBIO) shares are trading 9.5% higher after Roth Capital Partners raised its price target on the stock from $28 to $45. Roth Capital Partners in a Sunday research report noted the company has one-third of its research and development funds devoted to mRNA vaccines.

Why Translate Bio Shares Are Trading Higher Today

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate.

Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial --

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks -- LEXINGTON, Mass., June 07, 2021 (GLOBE NEWSWIRE) --  Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced it has achieved a manufacturing milestone under the collaboration with Sanofi Pasteur related to its influenza mRNA vaccine program. Translate Bio will receive a $50 million payment from Sanofi Pasteur for the successful manufacture, release, and delivery of clinical drug product to supply Sanofi Pasteur's Phase 1 influenza clinical trial which is anticipated to begin in the coming weeks. The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program.

Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program

LEXINGTON, Mass., May 24, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that the Company will participate in the following upcoming investor conferences:

Translate Bio to Participate in Upcoming Investor Conferences

Translate Bio Inc (NASDAQ: TBIO) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease.

Translate Bio's mRNA Therapeutic For Respiratory Tract Infections Shows Promise In Animal Studies

– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations –

Translate Bio Presents Preclinical Results in Primary Ciliary Dyskinesia (PCD) at American Thoracic Society (ATS) 2021 International Conference

Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -11.11% and -12.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Translate Bio, Inc. (TBIO) Reports Q1 Loss, Misses Revenue Estimates

-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year -- -- Reported interim data from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) --

Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update

Will Translate Bio, Inc. (TBIO) Report Negative Q1 Earnings? What You Should Know

BioNTech SE

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CRISPR Therapeutics

CureVac B.V

Editas Medicine

iShares Nasdaq Biotechnology ETF

Moderna

Pfizer

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 10:30 a.m. EST.

Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit

Translate Bio, Inc. is an early-clinical-stage biotechnology company developing mRNA therapeutics and vaccines targeting protein or gene dysfunction and infectious diseases respectively.

Translate Bio: New Management, Aggressive mRNA Pipeline Development, And Substantial Upside

- - Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringing strategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary programs, manufacturing and financial operations with a goal of advancing platform, preclinical and clinical milestones --

News for Telesis Bio Inc Stock (TBIO)